Aug 11, 2008|
Recession, in-licensing and more...
Falling oil fires up indicesAlso read - Is this the end for commodities?
Oil prices falling by US$ 5 a barrel on Friday to three-month lows sparked a rally in the indices in the US with the Dow and the Nasdaq gaining 3% each. The S&P 500 closed 2% higher. Dollar gaining strength against the Euro was also instrumental in bolstering the indices. With recession imminent in many countries of the European region, the Euro has been losing sheen thereby favouring the dollar. Oil has now retreated by around 20% since the high of US$ 147 that it had reached on July 11. Having said that, this optimism is likely to be a short blip on a broader canvas of sluggish growth and impending recession. While oil prices are moving downwards, uncertainty still abounds when it comes to ascertaining any definite direction. And the subprime malaise as of now simply refuses to go away.
Slowdown the world around
Recession seems to be catching up on the US, Europe and Japan. It has been a year since the credit crisis first made its impact felt and the world is still reeling under it with no immediate respite in sight. Meanwhile, inflation is scaling higher across the countries and central banks are probably busier than ever trying to keep their respective economies from going under. To put things into perspective, Japan's GDP shrunk by 2.3% in the three months ended June and faces the gloomy prospect of its first recession in six years. Britain is also struggling to keep its head above the water. As per reports, recession in Britain is expected to be deeper and last longer than in the US. This is because the country's two main industries namely housing and finance are in a state of turmoil. The problems in the US sparked by the subprime crisis and followed by falling house prices and gargantuan write downs by financial firms are well documented. The developing economies are also facing the heat with China and India struggling to battle the rising inflation.
This effectively means that a slowdown in economic growth seems inevitable and realising this, stockmarkets across the world are rapidly losing their sheen. Stocks that were trading at ridiculous valuations earlier have seen their prices crash and long term investors with a three to five year investment horizon can certainly take this opportunity and invest in sound companies with strong fundamentals and good managements. The pessimism prevailing all around should not dissuade serious investors to shy away from stocks and in fact they should capitalise on this opportunity to make some sound investments and reap the rewards in the long term.
Flavour of in-licensing catching on?Also read - Pharma: Why out-license?
It is a well know fact that Indian pharma companies in the past had largely been looking to out-license some of their potential candidates in the R&D (research and development) pipeline to global innovator companies in return for milestone payments. This achieved two purposes. One is that it enabled the immediate monetisation of their R&D assets, given the riskiness and the uncertainty surrounding the business and the second is that it provider a breather in terms of curtailing costs. The global innovator's better expertise in doing research was an added advantage. Amongst domestic pharma companies, Glenmark has been the most successful as compared to its peers in this regard managing to find partners for at least three of its molecules.
A reversal of roles is likely to slowly catch on and this was demonstrated by Ranbaxy, which in-licensed a molecule in the dermatology space from a Canadian company for development. As per the terms, it will be Ranbaxy that will be doling out milestone payments depending upon the progress of the molecule and bearing costs upto a pre-determined cap. Investors would do well to recollect that post the Daiichi deal, the R&D business of Ranbaxy will not be demerged into a separate company. The R&D efforts of Indian pharma companies are still in the nascent stages and while Ranbaxy's deal could set a trend going forward, it will be a while before these companies can match the resources and the capabilities of global pharma innovators.
More Views on News
Jun 10, 2017
Forty Indian investing gurus, as worthy of imitation as the legendary Peter Lynch, can help you get rich in the stock market.
Aug 22, 2017
It's surprising Warren Buffett hasn't warned investors about the expensive stock market? Let us know why.
Aug 22, 2017
Post demonetisation, a cut in bank savings deposits rates was in the offing.
Aug 22, 2017
Today, we are attacked by one preposterous thing after another, each of them even more absurd than the last.
Aug 21, 2017
Most Indians who cannot find jobs, look at becoming self-employed.
More Views on News
Aug 10, 2017
Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.
Aug 10, 2017
Bill connects the dots...between money and growth, real money and real resources, gold and cryptocurrencies...and between gold, cryptocurrencies, and time.
Aug 12, 2017
The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.
Aug 10, 2017
Bitcoin hits an all-time high, is there more upside left?
Aug 16, 2017
Ensure your financial Independence, and pledge to start the journey towards financial freedom today!
Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement. LEGAL DISCLAIMER:
Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here
. The performance data quoted represents past performance and does not guarantee future results.SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.
Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: email@example.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407